On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS Research, and the Stop TB Partnership Working Group on New Drugs. There will be live streaming available.
This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.
Microbial geneticist Dr. Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in research funding over five years. In this interview, we discuss the award and the related research that lead to the award, as well as, Dr. Lamichhane’s motivation to work with TB. Additional links to TB R&D news are included.
This week we highlight an article published out of Ying Zhang’s laboratory at Johns Hopkins University that puts forth a new model for the mode of action of pyrazinamide (PZA) and as well as suggest trans-translation as a potential target to consider in the development of new drugs for TB. Additional links to TB R&D news are included.
In this week”s TB R&D update, the WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled “PA-824 exhibits time-dependent activity in a murine model of tuberculosis” that we covered in a previous TB R&D Weekly Update. In the interview, Dr. Nuermberger provides an overview of his present research, key results presented in the article, and in vitro and preclinical testing of TB drug regimens. Also, links to additional news in TB R&D are included.
On Friday, June 11th, the Johns Hopkins University Center for Tuberculosis Research hosted their annual scientific meeting and the WGND was there to cover the event. Approximately 100-200 people were present including persons from NIH and small pharmaceutical companies. This annual meeting is an opportunity for the epidemiological, clinical and basic researchers to relate their [...]
Developing new TB drugs is inhibited by so many factors – namely: The flow through the TB drug pipeline is slow at best. Despite decades of hard work, we still use the demanding regimen developed 50 years ago – a regimen that requires patients to undergo 6-9 months of treatment consisting of four first-line TB [...]